Article thumbnail
Location of Repository

Comparative evaluation of the effect of statin drugs in Hyperlipidaemic patients

By Athimoolam Ambika Int J Cur Biomed Phar Res. Babu Shankar Ponnusha Boopathi subramaniyam Rajaram Virumandy Sathiyamoorthy Subramaniyam Govindaswamy Bakthavathsalam Palanisamy Pasupathi Jawahar Farook Y.Yagneswara Rao Suresh Pichandi


Background: Statins clearly confer substantial benefit in people with established cardiovascular (CV) disease (secondary prevention). The effectiveness of various statin drugs in hyperlipidaemic patients is evaluated in the present study. Aim: This work was undertaken to assess the effective role of statin in hyperlipidaemic patients with cardiovascular disease and comparison was made between various classes of statin drugs. Settings and Design: The study population contained 50 subjects with hyperlipidaemia and they were administered with statin class of drugs. Results: The administration of Rosuvastatin and Atrovastatin was found to be more effective in the treatment of hyperlipidaemic patients than that of Simvastatin and Pravastatin. Although flavostatin also had a profound effect, the dosage was high compared to other statins. Hence its effectiveness compared to Rosuvastatin and Atrovastatin need to be further investigated. Conclusions: Rosuvastatin and Atrovastatin can be more effective in reducing hyperlipidemia compared to other classes of statin drugs and thus further reduce the risk of cardiovascular disease in such patients.In addition to that,Rosuvasatin had less side effects in patients as compared to atrovastatin and can be defined as the most effective among the statin class of drugs

Publisher: CurrentSciDirect Publications
Year: 2011
OAI identifier:

Suggested articles


  1. (1997). A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy. Health Econ. doi
  2. (1998). A mathematical model for the determination of the optimum value of the treatment threshold for a continuous risk factor. doi
  3. Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency.
  4. (2001). Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.
  5. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.2006;9:565-581.
  6. (1999). Drug treatment of lipid disorders.
  7. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. doi
  8. (2011). Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. doi
  9. (1994). Global trends in health care reform. World Health Forum.
  10. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction.
  11. (2004). Paying for statins. BMJ.
  12. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.2004;
  13. (2003). Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.
  14. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMGCoA reductase inhibitor.Arterioscler Thromb Vasc Biol.1995;15
  15. (1993). Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential. Int J Technol Assess Health Care.
  16. (2005). Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.